EVOLUS Aktie

 

Moatazedi, David - Vorstand - Tag der Transaktion: 2025-06-16...

Moatazedi, David - Vorstand - Tag der Transaktion: 2025-06-13...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company's common stock to 17 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant date of June 8, 2025 and vesting commencement date of June 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $10.04 per share, the closing price of the company's common stock on June 6, 2025. The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to th...

White, Albert G III. - Aufsichtsrat - Tag der Transaktion: 2025-06-09...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

BURLINGAME, Calif.--(BUSINESS WIRE)--Lyra Health, the leading provider of mental health solutions for employers, has named Sandra Beaver as Chief Financial Officer, effective June 16. She brings exceptional business acumen and judgement, global public company experience, and expertise in complex international operations to the role. Sandra joins Lyra from Evolus, a publicly traded medical aesthetics company approaching $1 billion in market capitalization, where she has served as CFO since 2022. Prior to that role, she served as Senior Vice President of Finance at Experian with both North American and global responsibilities. Sandra spent the bulk of her career with global gaming company International Game Technology PLC (“IGT”) in roles of increasing responsibility and scope culminating in Chief Financial Officer of the company's North America Gaming and Interactive business unit. “It is a sincere pleasure to welcome Sandra to Lyra. Sandra is a warm and engaging leader who possesses an extraordinar...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver's resignation is not a result of any disagreement related to the company's operations, policies or practices, including any accounting principles and practices, or related to any financial statements or disclosures. “On behalf of our employees, our leadership team, and our Board of Directors, I want to thank Sandra for her contributions to Evolus,” said David Moatazedi, President and Chief Executive Officer of Evolus. “Her stewardship across several important functions has helped drive our consistent growth and positioned the company for continued success. We enter this next chapter with strong momentum, having recently launched our sec...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of non-qualified stock options to purchase an aggregate of 12,706 shares of Evolus and an aggregate of 40,576 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant date of May 12, 2025 and vesting commencement date of May 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $9.98 per share, the closing price of the company's common stock on the date of grant. The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to ...

Beaver, Sandra - Vorstand - Tag der Transaktion: 2025-05-13...

Moatazedi, David - Vorstand - Tag der Transaktion: 2025-05-12...

Avelar, Rui - Vorstand - Tag der Transaktion: 2025-05-12...

Evolus (EOLS) delivered earnings and revenue surprises of -80% and 4.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2025. “Coming off a record year, we enter 2025 with strong momentum,” said David Moatazedi, President and Chief Executive Officer of Evolus. “I...

Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based on current interest rates. The facility will mature five years from the funding date. Interest will be paid quarterly using the 3-month SOFR plus 5.00% per annum. Improved Structure & Financial Flexibility: Converted from an amortizing structure to a bullet maturity payment, with significantly reduced pre-payment fees, avoided any pre-payment fees from the existing facility, and additional considera...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13753202. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a g...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of April 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously emplo...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Moatazedi, David - Vorstand - Tag der Transaktion: 2025-03-27...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement date of March 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously employed on each vesting date. Abou...